204 related articles for article (PubMed ID: 17113707)
21. Inhibition of heat-shock protein 27 expression eliminates drug resistance of osteosarcoma to zoledronic acid.
Morii T; Ohtsuka K; Ohnishi H; Mochizuki K; Satomi K
Anticancer Res; 2010 Sep; 30(9):3565-71. PubMed ID: 20944138
[TBL] [Abstract][Full Text] [Related]
22. Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model.
Koto K; Horie N; Kimura S; Murata H; Sakabe T; Matsui T; Watanabe M; Adachi S; Maekawa T; Fushiki S; Kubo T
Cancer Lett; 2009 Feb; 274(2):271-8. PubMed ID: 18986762
[TBL] [Abstract][Full Text] [Related]
23. Alpha-tocopheryl succinate alters cell cycle distribution sensitising human osteosarcoma cells to methotrexate-induced apoptosis.
Alleva R; Benassi MS; Pazzaglia L; Tomasetti M; Gellert N; Borghi B; Neuzil J; Picci P
Cancer Lett; 2006 Feb; 232(2):226-35. PubMed ID: 16458119
[TBL] [Abstract][Full Text] [Related]
24. Sensitizing glioma cells to cisplatin by abrogating the p53 response with antisense oligonucleotides.
Datta K; Shah P; Srivastava T; Mathur SG; Chattopadhyay P; Sinha S
Cancer Gene Ther; 2004 Aug; 11(8):525-31. PubMed ID: 15167899
[TBL] [Abstract][Full Text] [Related]
25. Combined effects of bisphosphonate and radiation on osteosarcoma cells.
Ryu K; Murata H; Koto K; Horie N; Matsui T; Nishigaki Y; Sakabe T; Takeshita H; Itoi M; Kimura S; Ashihara E; Maekawa T; Fushiki S; Kubo T
Anticancer Res; 2010 Jul; 30(7):2713-20. PubMed ID: 20683003
[TBL] [Abstract][Full Text] [Related]
26. Growth of human tumor cells in macroporous microcarriers results in p53-independent, decreased cisplatin sensitivity relative to monolayers.
Maurer BJ; Ihnat MA; Morgan C; Pullman J; O'Brien C; Johnson SW; Rasey JS; Cornwell MM
Mol Pharmacol; 1999 May; 55(5):938-47. PubMed ID: 10220573
[TBL] [Abstract][Full Text] [Related]
27. RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines.
Yang C; Hornicek FJ; Wood KB; Schwab JH; Mankin H; Duan Z
Cancer Chemother Pharmacol; 2009 Aug; 64(3):607-14. PubMed ID: 19125251
[TBL] [Abstract][Full Text] [Related]
28. Differential effects of novel tumour-derived p53 mutations on the transformation of NIH-3T3 cells.
Donninger H; Binder A; Bohm L; Parker MI
Biol Chem; 2008 Jan; 389(1):57-67. PubMed ID: 18095870
[TBL] [Abstract][Full Text] [Related]
29. Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells.
Muraro M; Mereuta OM; Carraro F; Madon E; Fagioli F
Cell Immunol; 2007 Oct; 249(2):63-72. PubMed ID: 18163982
[TBL] [Abstract][Full Text] [Related]
30. Zoledronic acid determines S-phase arrest but fails to induce apoptosis in cholangiocarcinoma cells.
Romani AA; Desenzani S; Morganti MM; La Monica S; Borghetti AF; Soliani P
Biochem Pharmacol; 2009 Jul; 78(2):133-41. PubMed ID: 19464430
[TBL] [Abstract][Full Text] [Related]
31. The novel platinum(IV) complex LA-12 induces p53 and p53/47 responses that differ from the related drug, cisplatin.
Hrstka R; Powell DJ; Kvardova V; Roubalova E; Bourougaa K; Candeias MM; Sova P; Zak F; Fåhraeus R; Vojtĕsek B
Anticancer Drugs; 2008 Apr; 19(4):369-79. PubMed ID: 18454047
[TBL] [Abstract][Full Text] [Related]
32. Induction of apoptosis in osteogenic sarcoma cells by combination of tumor necrosis factor-related apoptosis inducing ligand and chemotherapeutic agents.
Sun J; Fu ZM; Fang CQ; Li JH
Chin Med J (Engl); 2007 Mar; 120(5):400-4. PubMed ID: 17376311
[TBL] [Abstract][Full Text] [Related]
33. Inorganic phosphate enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin via a p53-dependent pathway.
Spina A; Sorvillo L; Di Maiolo F; Esposito A; D'Auria R; Di Gesto D; Chiosi E; Naviglio S
J Cell Physiol; 2013 Jan; 228(1):198-206. PubMed ID: 22674530
[TBL] [Abstract][Full Text] [Related]
34. Berberine induces p53-dependent cell cycle arrest and apoptosis of human osteosarcoma cells by inflicting DNA damage.
Liu Z; Liu Q; Xu B; Wu J; Guo C; Zhu F; Yang Q; Gao G; Gong Y; Shao C
Mutat Res; 2009 Mar; 662(1-2):75-83. PubMed ID: 19159633
[TBL] [Abstract][Full Text] [Related]
35. Knockdown of CITED2 using short-hairpin RNA sensitizes cancer cells to cisplatin through stabilization of p53 and enhancement of p53-dependent apoptosis.
Wu ZZ; Sun NK; Chao CC
J Cell Physiol; 2011 Sep; 226(9):2415-28. PubMed ID: 21660965
[TBL] [Abstract][Full Text] [Related]
36. p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells.
Toscano F; Parmentier B; Fajoui ZE; Estornes Y; Chayvialle JA; Saurin JC; Abello J
Biochem Pharmacol; 2007 Aug; 74(3):392-406. PubMed ID: 17559811
[TBL] [Abstract][Full Text] [Related]
37. Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses.
Konstantakou EG; Voutsinas GE; Karkoulis PK; Aravantinos G; Margaritis LH; Stravopodis DJ
Int J Oncol; 2009 Aug; 35(2):401-16. PubMed ID: 19578756
[TBL] [Abstract][Full Text] [Related]
38. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines.
Noordhuis P; Laan AC; van de Born K; Losekoot N; Kathmann I; Peters GJ
Biochem Pharmacol; 2008 Jul; 76(1):53-61. PubMed ID: 18508032
[TBL] [Abstract][Full Text] [Related]
39. Differential role of diphenyleneiodonium, a flavoenzyme inhibitor, on p53-dependent and -independent cell cycle progression.
Song JD; Kim KM; Kim KH; Kim CD; Kim JM; Yoo YH; Park YC
Int J Oncol; 2008 Dec; 33(6):1299-306. PubMed ID: 19020764
[TBL] [Abstract][Full Text] [Related]
40. Mevalonate pathway inhibitors affect anticancer drug-induced cell death and DNA damage response of human sarcoma cells.
Nilsson S; Huelsenbeck J; Fritz G
Cancer Lett; 2011 May; 304(1):60-9. PubMed ID: 21356574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
